HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pressure On Opill Price From Lawmakers, Health Advocates, Not From Marketplace Competition

Executive Summary

Pressure from members of Congress and public and reproductive health advocacy groups will continue for making Opill’s price affordable to consumers from all income levels, but competition won’t affect the price for three years.

You may also be interested in...



Perrigo’s Rx-To-OTC Contraceptive Pill Switch Unanimously Rejected By German Committee

All nine present voting members of Germany's Expert Committee for Prescription rejected Perrigo's application to switch its progestogen-only contraceptive pill (desogestrel 75μg) from Rx to OTC status. 

Q4 Beauty Earnings Preview: China Volatility In 2023 Has Analysts Leery Of Big Beauty’s Results

Shiseido, L’Oreal and The Estee Lauder Companies are preparing to announce earnings results for the final three months of 2023, and all are expected to report headwinds that held back performance in China. Analysts anticipate a strong fourth quarter from Coty, which has been largely insulated from the ups and downs of the Chinese market in recent years.

US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel